Jonathan Piccini
Cardiovascular Disease · Durham, NCNPI 1003884693
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $537,728 of the $766,852 with a category attached, or 70.1%. 22 manufacturers reported payments, led by Boston Scientific at 37.9% of the total. Reporting peaked in 2023 at $357,917 and has fallen 80.0% since, to $71,531 in 2025. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 607 payments — averaging $1263.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$291K
- Medtronic$167K
- Abbott$113K
- Sanofi-aventis U.S. LLC$79K
- Philips North America LLC$50K
- AbbVie$24K
- plus $43K from 16 others
Across 294 payments — averaging $47,479 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi-aventis U.S. LLC$11.3M
- Irhythm Technologies, Inc.$723K
- Abbott$476K
- Boston Scientific$474K
- Philips North America LLC$376K
- Biotronik Inc.$276K
- plus $298K from 6 others
What the payments were for
- Consulting fees$537,72870%
- Speaking & faculty fees$158,36321%
- Grants$4380%
- Travel & lodging$56,8207%
- Food & beverage$13,5042%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 62 | $290,902 |
| Medtronic(2 entities) | 235 | $166,943 |
| Abbott | 114 | $113,364 |
| Sanofi-aventis U.S. LLC | 31 | $78,997 |
| Philips North America LLC | 56 | $50,110 |
| AbbVie(2 entities) | 26 | $23,934 |
| E.r. Squibb & Sons, L.L.C. | 5 | $15,680 |
| Livanova USA, Inc. | 38 | $11,000 |
| Pfizer | 3 | $4,200 |
| Biotronik Inc. | 12 | $3,893 |
| Bayer | 10 | $2,148 |
| Eli Lilly | 2 | $1,800 |
| Pacira Pharmaceuticals Incorporated | 1 | $1,640 |
| Altathera Pharmaceuticals LLC | 1 | $1,000 |
| Janssen Research & Development, LLC | 3 | $297 |
| Volta Medical Inc | 2 | $236 |
| Novartis | 1 | $205 |
| Cortex, Inc. | 1 | $172 |
| Biosense Webster, Inc. | 1 | $118 |
| Acutus Medical, Inc. | 1 | $98 |
| LSI Solutions Inc | 1 | $83 |
| Atricure, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MULTAQ$68,218
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$39,415
- (9520) IGT Devices Undivided$33,818
- Micra$26,914
- TactiCath Quartz CFA Catheter$25,056
- ENSITE PRECISION$24,893
- FLEXABILITY$10,366
- ARCTIC FRONT ADVANCE$8,938
- CLINICAL TRIAL PRODUCT$8,506
- Bridge$7,238
- VNS - Vitaria$6,550
- Watchman$6,456
- Arctic Front$6,200
- Spectranetics Undiv$5,500
- GENERAL - THERAPIES$4,439
- ELIQUIS$4,200
- Epic$4,130
- VNS Therapy$3,850
- AMPLATZER PICCOLO$3,135
- ENSITE$1,946
How this compares
$766,852 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 323 | $327,683 |
| MultaqDronedarone Hcl | 64 | $93,638 |
| XareltoRivaroxaban | 60 | $72,165 |
| Metoprolol Succinate | 199 | $3,764 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 21 | $3,645 |
| Dofetilide | 13 | $3,077 |
| Amiodarone Hcl | 171 | $2,962 |
| Flecainide Acetate | 17 | $1,838 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 41 | $1,131 |
| Carvedilol | 30 | $277 |
| SotalolSotalol Hcl | 19 | $194 |
| Lisinopril | 13 | $129 |
| Metoprolol Tartrate | 15 | $113 |
| Atenolol | 11 | $89 |
| ClopidogrelClopidogrel Bisulfate | 17 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $4,200 | $327,683323 claims |
| Sanofi-aventis U.S. LLCMultaq | $78,997 | $93,63864 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Durham
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Robert MentzDurham$489K
- Adrian HernandezDurham$409K
- Neha PagidipatiDurham$301K
- Joseph KissloDurham$283K
- Mitchell KrucoffDurham$281K
- Ankeet BhattDurham$258K
- Christopher GrangerDurham$257K
- Gary FelkerDurham$256K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.